Patil KR and Patil CR. 2017. Anti-inflammatory activity of bartogenic acid containing fraction of fruits of Barringtonia racemosa Roxb. in acute and chronic animal models of inflammation. J Trad Complement Med. https://doi.org/10.1016/j.jtcme.2016.02.001.
Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X and Zhao L. 2018. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. https://doi.org/10.18632/oncotarget.23208.
Kany S, Vollrath JT, Relja B. Cytokines in inflammatory disease. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20236008.
Article PubMed PubMed Central Google Scholar
Adams C, Conigrave JH, Lewohl J, Haber P, Morley KC. Alcohol use disorder and circulating cytokines: a systematic review and meta-analysis. Brain Behav Immun. 2020. https://doi.org/10.1016/j.bbi.2020.08.002.
Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007. https://doi.org/10.1097/AIA.0b013e318034194e.
Article PubMed PubMed Central Google Scholar
Tan JL, Lash B, Karami R, Nayer B, Lu YZ, Piotto C, Julier Z, Martino MM. Restoration of the healing microenvironment in diabetic wounds with matrix-binding IL-1 receptor antagonist. Commun Biol. 2021. https://doi.org/10.1038/s42003-021-01913-9.
Article PubMed PubMed Central Google Scholar
Naik S, Larsen SB, Gomez NC, Alaverdyan K, Sendoel A, Yuan S, Polak L, Kulukian A, Chai S, Fuchs E. Inflammatory memory sensitizes skin epithelial stem cells to tissue damage. Nature. 2017. https://doi.org/10.1038/nature24271.
Article PubMed PubMed Central Google Scholar
Nosenko MA, Ambaryan SG, Drutskaya MS. Proinflammatory cytokines and skin wound healing in mice. Mol Biol. 2019. https://doi.org/10.1134/S0026898419050136.
Akash MSH, Rehman K, ChenS. IL-1RA and its delivery strategies: inserting the association in perspective. Pharm Res. 2013. https://doi.org/10.1007/s11095-013-1118-0.
Abbate A, Toldo S, Marchetti C, Kron J, Van-Tasseli BW, Dinarello CA. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020. https://doi.org/10.1161/CIRCRESAHA.120.315937.
Article PubMed PubMed Central Google Scholar
Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006. https://doi.org/10.1038/nature05485.
Yan C, Gao N, Sun H, Yin J, Lee P, Zhou L, Fan X, Yu FS. Targeting imbalance between IL-1β and IL-1 receptor antagonist ameliorates delayed epithelium wound healing in diabetic mouse corneas. Am J Pathol. 2016. https://doi.org/10.1016/j.ajpath.2016.01.019.
Article PubMed PubMed Central Google Scholar
Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004. https://doi.org/10.1016/S1074-7613(04)00046-9.
Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009. https://doi.org/10.1146/annurev.immunol.021908.132612.
Walle LV, Opdenbosch NV, Jacques P, Fossoul A, Verheugen E, Vogel P, Beyaert R, Elewaut D, Kanneganti TV, Loo GV, Lamkanti M. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature. 2014. https://doi.org/10.1038/nature13322.
Article PubMed Central Google Scholar
Dinarello CA, Van-Der-Meer JWM. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013. https://doi.org/10.1016/j.smim.2013.10.008.
Article PubMed PubMed Central Google Scholar
Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013. https://doi.org/10.1016/j.immuni.2013.11.010.
Article PubMed PubMed Central Google Scholar
Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol. 2018. https://doi.org/10.3389/fphar.2018.01157.
Article PubMed PubMed Central Google Scholar
Stredny CM, Siobhan C, Sansevere AJ, Marybeth F, Henderson L, Gorman MP. Interleukin-6 blockade with tocilizumab in anakinra-refractory febrile infection- related epilepsy syndrome (FIRES). Child neurology open. 2020. https://doi.org/10.1177/2329048X20979253.
Article PubMed PubMed Central Google Scholar
Somagutta MKR, Pormento MKL, Hamid P, Hamdan A, Khan MA, Desir R, Vijayan R, Shirke S, Jeyakumar R, Dogar Z, Makkar SS, Guntipalli P, Ngardig NN, Nagineni MS, Paul T, Luvsannyam E, Riddick C, Sanchez-Gonzalez MA. The safety and efficacy of anakinra, an interleukin-1 antagonist in severe cases of COVID-19: a systematic review and meta-analysis. J Infect Chemother. 2021. https://doi.org/10.3947/ic.2021.0016.
Klementiev B, Li S, Korshunova I, Dmytriyeva O, Pankratova S, Walmod PS, Kjær LK, Dahllöf MS, Lundh M, Christensen DP, Mandrup-Poulsen T, Bock E, Berezin V. Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist. J Neuroinflammation. 2014. https://doi.org/10.1186/1742-2094-11-27.
Article PubMed PubMed Central Google Scholar
Machado-de-Ávila RA, Velloso M, Oliveira D, Stransky S, Flor-Sá A, Schneider FS, Neshich G, Chávez-Olórtegui C. Induction of neutralizing antibodies against mutalysin-II from Lachesis muta muta snake venom elicited by a conformational B cell epitope predicted by Blue Star Sting data base. Immunome Res. 2014. https://doi.org/10.4172/1745-7580.1000083.
Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997. https://doi.org/10.1002/elps.1150181505.
Merrifield RB. Solid-phase peptide synthesis. Adv Enzymol Relat Areas Mol Biol. 1969. https://doi.org/10.1002/0471140864.ps1801s26.
Martin P, Goldstein JD, Mermoud L, Diaz-Barreiro A, Palmer G. IL-1 family antagonists in mouse and human skin inflammation. Front Immunol. 2021. https://doi.org/10.3389/fimmu.2021.652846.
Article PubMed PubMed Central Google Scholar
Supino D, Minute L, Mariancini A, Riva F, Magrini E, Garlanda C. Negative regulation of the IL-1 system by IL-1R2 and IL-1R8: relevance in pathophysiology and disease. Front Immunol. 2022. https://doi.org/10.3389/fimmu.2022.804641.
Article PubMed PubMed Central Google Scholar
Kluczyk A, Siemiona IZ, Wieczorek Z. The “two-headed” peptide inhibitors of interleukin-1 action. Peptides. 2000. https://doi.org/10.1016/s0196-9781(00)00285-0.
Barkestani MN, Naserian S, Khoddam F, Shamdani S, Bambai B. Optimization of IL-1RA structure to achieve a smaller protein with a higher affinity to its receptor. Sci Rep. 2022. https://doi.org/10.1038/s41598-022-11100-3.
Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A, Bowlin T, Yanofsky S, Rw B. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature. 2001. https://doi.org/10.1038/386194a0.
Kaneko N, Kurata M, Yamamoto T, Morikawa S, Masumoto J. The role of interleukin- 1 in general pathology. Inflamm Regen. 2019. https://doi.org/10.1186/s41232-019-0101-5.
Article PubMed PubMed Central Google Scholar
Rider P, Carmi Y, Yossef R, Guttman O, Eini H, Azam T, Dinarello CA, Lewis EC. IL-1 receptor antagonist chimeric protein: context-specific and inflammation-restricted activation. J Immunol. 2015. https://doi.org/10.4049/jimmunol.1501168.
Oliviero F, Sfriso P, Punzi L, Dayer JM. Editorial: IL-1 inhibition. Front Pharmacol. 2019. https://doi.org/10.3389/fphar.2019.00087.
Article PubMed PubMed Central Google Scholar
Ozen G, Pedro S, England BR, Mehta B, Wolfe F, Michaud K. Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease-modifying antirheumatic drugs. ACR Open Rheumatol. 2019. https://doi.org/10.1002/acr2.11064.
Article PubMed PubMed Central Google Scholar
Deigin VI, Poluektova EA, Beniashvili AG, Kozin SA, Poluektov YM. Development of peptide biopharmaceuticals in Russia. Pharmaceutics. 2022. https://doi.org/10.3390/pharmaceutics14040716.
Comments (0)